• Explore /
  • Poster
  • / First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.

Abstract Poster

Authors

null

Yu Chen

Fujian Cancer Hospital, Fuzhou, China

Yu Chen , Jing Lin , Hui Wang , Weizhen Zhang , Xinjun Liang , Jiuwei Cui , Yuping Sun , Meiyu Fang , Yueyin Pan , Qian Chu , Xueli Bai , Jian Zhang , Ning Li , Xiaoshi Zhang , Li Zhao , Haonan Chen , Hongli Wang , Yuling Chen , Xing Sun , Hui Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05460767

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 9562)

DOI

10.1200/JCO.2024.42.16_suppl.9562

Abstract #

9562

Poster Bd #

346

Abstract Disclosures

Similar Posters

First Author: Ahmad A. Tarhini

First Author: Panpan Zhang

First Author: Joachim Aerts

First Author: Fengchun Mu